EP
WHWK

Eversept Partners’s Whitehawk Therapeutics WHWK Stock Holding History

Eversept Partners’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Buy
306,800
+46,541
+18% +$146K 0.06% 106
2025
Q4 		$630K Buy
+260,259
New +$597K 0.03% 102
2023
Q4 		– Sell
-101,918
Closed -$493K – 72
2023
Q3 		$493K Hold
101,918
– – 0.04% 68
2023
Q2 		$697K Hold
101,918
– – 0.06% 67
2023
Q1 		$738K Hold
101,918
– – 0.05% 60
2022
Q4 		$1.31M Hold
101,918
– – 0.11% 57
2022
Q3 		$1.44M Buy
101,918
+1,101
+1% +$14.5K 0.12% 56
2022
Q2 		$1.24M Sell
100,817
-50,000
-33% -$743K 0.09% 62
2022
Q1 		$2.56M Buy
+150,817
New +$2.89M 0.2% 58

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Eversept Partners's WHWK Position: Q1 2026 in Review

Eversept Partners increased its Whitehawk Therapeutics (WHWK) stake by 18% in Q1 2026, buying an estimated $146K and bringing the position to 306,800 shares worth $1.06M. The position accounts for 0.06% of the portfolio, ranked #106.

Eversept Partners first reported a position in WHWK in Q1 2022 and has held it in 9 quarters since. The position peaked at $2.56M in Q1 2022. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Eversept Partners held 306,800 shares of Whitehawk Therapeutics worth $1.06M as of Q1 2026.
  • Eversept Partners bought 46,541 Whitehawk Therapeutics shares in Q1 2026, an estimated $146K.
  • Whitehawk Therapeutics made up 0.06% of Eversept Partners's portfolio in Q1 2026, its #106 holding.
  • Eversept Partners first reported a position in Whitehawk Therapeutics in Q1 2022 and has held it in 9 quarters since.
  • Eversept Partners's Whitehawk Therapeutics position peaked at $2.56M in Q1 2022.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.